INFORMATION BY CANCER TYPE
David McDermott, M.D. discusses new advances made to treat kidney cancer.
An independent data monitoring committee recommended that the phase 3 ADAPT trial exploring rocapuldencel-T (AGS-003) for the frontline treatment of metastatic renal cell carcinoma (mRCC) be stopped, but Argos Therapeutics explained that they will keep the trial open.
A randomized trial showed that the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) has some promise for the frontline treatment of some patients with RCC.
A recent study found that patients with metastatic renal cell carcinoma may see extended response even after stopping immunotherapy treatment.
Patients with metastatic kidney cancer may see a decreased efficacy of their immunotherapy regimen if they recently took antibiotics.
Sutent treatment breaks seem to have no effect on clinical efficacy for patients with renal cell carcinoma.
CURE spoke with Neeraj Agarwal, M.D., about the underreporting and underemphasizing of toxicities with PD-1 inhibitors in renal cell carcinoma.
Vaccines are currently being tested in their potential to improve immunotherapy responses for patients with renal cell carcinoma.
Elizabeth Plimack, M.D., discusses an update on the CheckMate-025 trial, comparing Opdivo to Afinitor in patients with metastatic renal cell carcinoma.
David F. McDermott, M.D., is optimistic about combination regimens shaping the treatment landscape for renal cell carcinoma.